Skip to main content

Medication

Adverse effects

Girl with CGM

21-09-2022 | EASD 2022 | Conference coverage | News

Skin reactions rarely lead to diabetes device discontinuation

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.

Nicola Milne

12-09-2022 | GLP-1 agonists | Ask the expert | Article

Initiating GLP-1 receptor agonists: Managing side effects

Specialist nurse Nicola Milne discusses the side effects that can arise in people with type 2 diabetes during initiation of GLP-1 receptor agonists, and how to best manage them.

30-06-2022 | Adverse effects | News

Meta-analysis flags cholecystitis risk with DPP-4 inhibitor treatment

People taking dipeptidyl peptidase-4 inhibitors to treat type 2 diabetes may have an increased risk for cholecystitis, especially with longer duration of treatment, show findings of a meta-analysis.

13-05-2022 | Insulin | News

Clinical criteria can identify insulin allergy

Researchers have identified four simple clinical criteria that can be used to predict the likelihood of insulin allergy and guide decisions about the need for confirmatory allergy testing.

Newborn baby

29-03-2022 | Metformin | News

Paternal metformin exposure linked to increased birth defect risk

The risk for a birth defect may be increased if the father is taking metformin around the time of spermatogenesis, say researchers.

John Wilding

19-01-2022 | Hyperglycemia | View from the clinic | Article

Corticosteroid treatment and the consequences for glucose control

John Wilding highlights the issue of hyperglycemia triggered by use of high-dose steroids and discusses management strategies.

26-08-2021 | ESC 2021 | Conference coverage | News

Canagliflozin may protect against hyperkalemia in type 2 diabetes with CKD

Canagliflozin may reduce the risk for hyperkalemia, without increasing hypokalemia, in people with type 2 diabetes and chronic kidney disease receiving renin–angiotensin–aldosterone system inhibitors, shows a CREDENCE post-hoc analysis.

Retina image

13-08-2021 | SGLT2 inhibitors | News

SGLT2 inhibitors linked to retinal vein occlusion in type 2 diabetes

New users of SGLT2 inhibitors are more likely to develop retinal vein occlusion than those initiating other glucose-lowering drugs, suggest results from a South Korean study.

SGLT2 inhibition

10-06-2021 | Adverse effects | News

Steep eGFR drop on SGLT2 inhibitor initiation may pose cardiorenal risk

The small proportion of people who experience an eGFR fall of more than 30% on starting an SGLT2 inhibitor may be at increased risk for adverse outcomes, research suggests.

Kidney stones

30-03-2021 | SGLT2 inhibitors | News

Treatment with SGLT2 inhibitors may reduce risk for kidney stones

SGLT2 inhibitor treatment could lower the risk for incident and recurrent kidney stones in people with type 2 diabetes, suggest Danish study results.

Diabetes medications

21-01-2021 | SGLT2 inhibitors | News

Meta-analysis underscores individual risk profile impact on GLP-1, SGLT2 benefits

A network meta-analysis highlights the impact of individual risk profiles on the absolute benefits offered by GLP-1 receptor agonists and SGLT2 inhibitors for people with type 2 diabetes.

04-09-2020 | Canagliflozin | News

FDA removes amputation Boxed Warning from canagliflozin label

Click through to read more on this announcement

02-09-2020 | Canagliflozin | News

Age, cardiovascular disease impact amputation risk with canagliflozin

Older patients and those with cardiovascular disease are most likely to have an increased risk for lower limb amputation when newly prescribed canagliflozin, relative to a GLP-1 receptor agonist, research shows.

28-08-2020 | Metformin | News

Early risk for anemia associated with metformin use in type 2 diabetes

Metformin consistently causes an early reduction in hemoglobin and increases the risk for moderate anemia in patients with type 2 diabetes, a MASTERMIND consortium analysis shows.

19-08-2020 | SGLT2 inhibitors | News

Data reject SLGT2 inhibitor link to increased amputation risk

The risk for lower limb amputation is not significantly increased among people using SGLT2 inhibitors to treat type 2 diabetes, according to findings from two studies.

14-08-2020 | Dapagliflozin | News

Dapagliflozin not linked to adverse limb events in DECLARE-TIMI 58

Dapagliflozin reduces the risk for cardiovascular events in people with type 2 diabetes, including those with peripheral artery disease, without increasing the risk for adverse limb events, show DECLARE-TIMI 58 data.

07-08-2020 | Adverse effects | News

Case of canagliflozin-triggered rosuvastatin-induced myotoxicity reported

Canadian clinicians have reported the case of a woman on long-term rosuvastatin treatment who developed rhabdomyolysis within days of starting on canagliflozin.

06-02-2020 | Rosiglitazone | News

Individual patient data analysis firms up rosiglitazone safety verdict

An individual patient data meta-analysis confirms the increased heart failure risk associated with rosiglitazone and lends some support to an elevated myocardial infarction risk.

Cervical hip (femoral neck) fracture

23-08-2019 | Canagliflozin | Highlight | News

CANVAS canagliflozin fracture effect may be chance finding

A comparison of CANVAS and CANVAS-R fails to detect any potential explanation for the increased fracture risk seen with canagliflozin versus placebo in the former trial.

Urine test strip

29-07-2019 | SGLT2 inhibitors | Highlight | News

Real-world data reassure on severe UTI risk with SGLT2 inhibition

The risk for severe urinary tract infections among people with type 2 diabetes in the real-world setting may be no greater with use of sodium-glucose cotransporter 2 inhibitors than with other modern antidiabetes medications, research suggests.